Citeline Podcast Special: The Shifting Landscape For Drugs And Devices Post-Roe v. Wade
Executive Summary
A special podcast featuring editors Elizabeth Orr and Marion Webb from Medtech Insight, Brenda Sandburg from Pink Sheet and Malcolm Spicer from HBW Insight discussing the US Supreme Court’s historic overturning of Roe v. Wade and implications for FDA-regulated sectors, from the abortion pill and OTC daily and emergency contraceptives to intrauterine devices and period-tracking apps.
Listen to the podcast below:
Articles discussed in this podcast:
-
US FDA Has 10 Months To Provide Answer On Perrigo/HRA OTC Oral Contraceptive Application
-
Allowing States To Ban Abortion Services Increases Calls For Making Birth Control Available OTC
-
OTC Switch For Daily Oral Contraceptive Brandished In Senate Health Care Policy Duel
-
Barriers To US OTC Emergency Contraceptive Sales Remain Despite Court Rebuke Of Restrictions
-
Expanding US OTC Switches Turns On Flexibility In FDA Drug Approval Process And For Consumers
-
Dual Rx/OTC Status In US ‘Additional Condition’ Switch Proposal: Necessary Or Questionable?
-
US FDA May Play Central Role In Assuring Access To Mifepristone Post Roe v. Wade
-
Mifepristone Access Imperiled By Supreme Court’s Draft Decision Overturning Abortion Rights
-
With Roe v. Wade In Rearview, What’s Next For Women’s Health
-
Telemedicine Among Sticky Wickets As Uncertainty Abounds Post-Roe v. Wade
-
Period-Tracking Apps Should Safeguard Data, Reassure Customers In Post-Roe Era
Find more episodes on the Medtech Insight podcast page. These and other Informa Pharma Intelligence podcasts also are available on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn, and Spotify Podcasts, as well as smart speakers if the platforms have been set up as the default podcast provider.